- Dynavax press release ( NASDAQ: DVAX ): Q2 GAAP EPS of $0.87 beats by $0.65 .
- Revenue of $256.46M (+386.0% Y/Y) beats by $105.47M .
- Cash and Marketable Securities. Cash and marketable securities were $518.2 million as of June 30, 2022.
- 2022 Financial Guidance: Full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million, with an associated gross margin anticipated to be approximately 60%
- Research and development expenses to be between approximately $50-$60 million
- Selling, general and administrative expenses to be between approximately $130-$140 million
- Interest expense of approximately $7 million
- Shares +3.21% .
For further details see:
Dynavax GAAP EPS of $0.87 beats by $0.65, revenue of $256.46M beats by $105.47M